Full-Time
Certified Registered Nurse Anesthetist
Ingalls
Posted on 10/3/2025
The University of Chicago Medicine
5,001-10,000 employees
Academic medical center delivering patient care
No salary listed
Markham, IL, USA
In Person
 Medical, Clinical & Veterinary (1) |
|---|
- Baccalaureate or Graduate Degree in Nursing or other appropriate majors
- An unencumbered license as a Registered Professional Nurse and/or APRN
- A minimum of one year of full-time work experience, or its part-time equivalent, as a registered nurse in a critical care setting within the United States
- Graduation with a minimum of a master’s degree from a Nurse Anesthesia Educational Program accredited by the Council on Accreditation of Nurse Anesthesia Educational Programs
- Passed the National Certification Examination
- BLS and ACLS certificate required
- Administering anesthesia to a patient
- Maintaining anesthesia during an operation
- Managing recovery from anesthesia
- Performs preoperative assessment of the patient, which includes chart review, preop patient interview, history and physical if necessary, and establishes an anesthesia plan based on findings and discussion with the surgeon and attending anesthesiologist
- Demonstrates an expert proficiency in airway management, which includes mask ventilation, laryngeal mask ventilation, endotracheal intubation
- Case types include General surgery, Ortho, Spine, OB/GYN, Ophthalmology, Urology. Limited healthy pediatrics at Ambulatory Surgery Center (ASC), rare cranis, no trauma
- Anesthesia Care Team (ACT) model, in which an anesthesiologist concurrently supervises non-physician anesthetists and/or anesthesiology residents at both UChicago Medicine Ingalls Memorial Hospital and Tinley Park Ambulatory Surgery Center (ASC)
- Neuraxial experience preferred but not required
The University of Chicago Medicine provides comprehensive healthcare through its Hyde Park campus, regional facilities, and outpatient clinics, backed by the Medical Center, Pritzker School of Medicine, and the Biological Sciences Division. It offers specialized care across more than 40 institutes and centers, including an NCI-designated Comprehensive Cancer Center, with 805 licensed beds, about 850 attending physicians, around 2,500 nurses, and over 1,100 residents and fellows. Care is delivered by clinical teams in hospitals and clinics, with ongoing research and education that translate new knowledge into treatments and train the next generation of clinicians. As an academic medical center that links a hospital system with a medical school and biology division, it combines patient care, medical education, and biomedical research while serving a regional network in the Chicago area.
Company Size
5,001-10,000
Company Stage
Grant
Total Funding
$112.4M
Headquarters
Chicago, Illinois
Founded
1927
Simplify's Take
What believers are saying
- Artisight deployment cuts fall rates 78% and boosts on-time discharges 4x across UChicago Medicine.
- Ralph Lauren Center expands cancer care to South Side via 2026 Ingalls launch and 2027 pavilion.
- 24/7 Partum Health doulas enhance birth equity and satisfaction at UChicago Family Birth Center.
What critics are saying
- Artisight's 1,800 AI devices expose UChicago Medicine to cyberattacks disrupting patient data by November 2026.
- iMRI suite's overhyped claims without outcome data erode physician trust by November 2027.
- Tegoprubart trial triggers graft failures, FDA halt, and Transplant Institute lawsuits by November 2026.
What makes The University of Chicago Medicine unique
- Artisight's unified sensor platform spans patient rooms, ORs, and PACUs across 1,800 devices at UChicago Medicine.
- First-in-Chicago PPIBD Clinic integrates gastroenterology, maternal-fetal medicine, and intestinal ultrasound for IBD pregnancies.
- Tegoprubart trial achieves insulin independence in type 1 diabetes islet transplants without calcineurin inhibitors.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Tuition Reimbursement
Company News
U Chicago partners with Partum Health to staff doulas around the clock. Partum Health doulas pose for a photo at doula training at U Chicago Medicine. Starting Tuesday, doulas are available 24/7 at UCM Birthing Center in Hyde Park. Partum Health Starting Tuesday, a team of full-spectrum doulas with Chicago-based startup Partum Health will be working around the clock alongside the doctors, midwives and nurses at the University of Chicago Medicine Family Birth Center in Hyde Park. "This is just a really exciting way that we have been able to partner to take legislation in a way that it actually touches patients and is going to be improving health equity and birth outcomes, patient satisfaction and efficiency in a hospital," said Dr. Melissa Dennis, Chief Medical Officer at Partum. She said having doulas on staff 24/7 means patients don't have to worry about pre-arranging doula support. Historically, patients would have find doulas and pay for them on their own. Partum Health "Now, what we're doing is creating an environment where, when patients show up to the family birth center, there will be a doula available to support them in labor if they have not pre-arranged to have a doula supporting them," Dr. Dennis said. Doulas are trained non-clinical professionals who offer personalized physical, emotional and informational support to patients. Dr. Dennis said research shows that when patients work with doulas, they have a better birthing experience. "Most of our doulas who we have hired are from the community or have always served the community in the South Side of Chicago and are committed to health equity and to ensuring that these voices are heard," she said. She said it's part of a larger goal where a higher standard of care is the new standard of care. "This is just a way that they have that additional support that they need to make this the safest and most joyful experience that they can have while entering to give birth," she said.
Tegoprubart enables insulin independence in type 1 diabetes Islet Transplant study. New data show tegoprubart enabled insulin independence and strong glycemic control in adults with long-standing type 1 diabetes undergoing islet transplantation. Eledon Pharmaceuticals has announced updated results from an investigator-initiated trial of 12 adults with long-standing type 1 diabetes undergoing allogeneic islet transplantation who received tegoprubart as part of a calcineurin inhibitor-free immunosuppression regimen. The pilot study was conducted at the University of Chicago Medicine Transplant Institute and results were presented by Piotr Witkowski, MD, PhD, director of the Pancreas and Islet Transplant Program at UChicago Medicine, at the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Barcelona, Spain. "T1D patients have been waiting decades for a potential functional cure, and it is very encouraging to see meaningful progress in that direction through the emerging promise of tegoprubart," David-Alexandre Gros, MD, Chief Executive Officer of Eledon, said in a statement. "These latest findings support the potential of tegoprubart to enable effective islet graft protection while avoiding the toxicities often associated with calcineurin inhibitors, and potentially enable access to islet cell transplantation for individuals living with T1D. We are proud to contribute to these important ongoing research efforts and support the work of Dr. Witkowski and the team at UChicago Medicine. We also look forward to working closely with the FDA towards our goal of receiving regulatory guidance on a path to market for tegoprubart in islet cell transplantation later this year." Tegoprubart is a humanized monoclonal antibody that selectively inhibits CD40 ligand, a co-stimulatory molecule in T cell activation. It is being explored in preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver allograft transplantation and amyotrophic lateral sclerosis. In nephrology, phase 2 BESTOW trial data suggest tegoprubart provides comparable efficacy and superior safety to tacrolimus as the core immunosuppressant in de novo kidney transplant recipients. The latest study in adults with long-standing type 1 diabetes included patients undergoing allogeneic islet transplantation at UChicago Medicine. Participants had a median duration of diabetes of approximately 33 years, a mean hemoglobin A1C of approximately 8.0% prior to transplantation, and received tegoprubart as part of a calcineurin inhibitor-free immunosuppression regimen. Data presented at ATTD showed rapid improvement in glycemic control following islet transplantation, with stable islet graft function observed across the cohort. All 10 patients who were > 4 weeks post-transplant achieved both insulin independence and a most recent HbA1c < 6.0%, with a mean most recent HbA1c across the 10 patients of approximately 5.35%. Of note, tegoprubart-based immunosuppression was generally well tolerated with reported post-transplant immunosuppression-related adverse events successfully treated by lowering the mycophenolic acid dose, if necessary. There were no rejection episodes, and no patients developed de novo donor-specific HLA antibodies. Additionally, no evidence of nephrotoxicity, hypertension or neurotoxicity was observed. The UChicago Medicine-initiated clinical trial is funded by Breakthrough T1D, with additional commitment to fund a second study evaluating tegoprubart as part of a calcineurin inhibitor-free immunosuppression drug regimen to prevent islet transplant rejection in individuals with T1D and chronic kidney disease. "Breakthrough T1D is proud to fund the University of Chicago's clinical trial testing tegoprubart as a novel immunosuppression alternative for use in islet cell transplants and we are very encouraged by the early data," said Aaron Kowalski, PhD, CEO of Breakthrough T1D. "It is exciting to see islet transplant recipients in this trial who no longer need to administer insulin and who are experiencing fewer side effects than with traditional immunosuppressive regimens."
Chicago's top medical centers make global impact as northwestern Memorial, rush University, and University of Chicago earn spots on Newsweek's 2026 World's Best Hospitals list. CHICAGO, ILLINOIS - Three of Chicago's leading hospitals have secured prestigious placements on Newsweek's 2026 "World's Best Hospitals" list, reinforcing the city's reputation as a global hub for advanced medical care and patient-centered treatment. The annual ranking, now in its eighth year, evaluated more than 2,500 hospitals worldwide and recognized the top 250 institutions for excellence in healthcare delivery, patient outcomes, and overall performance. Northwestern Memorial leads Illinois hospitals. Northwestern Memorial Hospital earned the highest ranking among Illinois hospitals, coming in at No. 61 globally. It was also the only hospital in the state to receive a PROMs ribbon - a distinction tied to Patient-Reported Outcome Measures (PROMs). PROMs evaluate how patients perceive their well-being and quality of life after treatment, offering insight into real-world recovery experiences beyond traditional clinical metrics. Rush and University of Chicago also recognized. Rush University Medical Center followed at No. 130, while University of Chicago Medical Center secured the No. 135 spot on the global list. All three institutions were evaluated using four major data sources: * Recommendations from medical professionals * Hospital quality metrics * Patient experience data * Results from Statista's PROMs survey The methodology blends expert opinion with patient feedback and measurable performance standards, aiming to provide a comprehensive look at hospital quality across the globe. How the global rankings compare. Outside of Illinois, Mayo Clinic once again claimed the No. 1 overall ranking worldwide, marking its eighth consecutive year at the top of the list. The global competition includes major academic medical centers and healthcare systems from Europe, Asia, and North America, making the inclusion of three Chicago hospitals a significant achievement for the city's healthcare landscape. Why this matters. Recognition on an international ranking like Newsweek's carries weight beyond prestige. For patients, it signals high standards of care, advanced research capabilities, and a commitment to improving long-term outcomes. Chicago's continued presence on the list highlights the strength of its healthcare institutions and their role in shaping modern medicine. Do you or your family rely on any of these hospitals? Share your experiences and thoughts with Saludastandard Sentinel at SaludaStandard-Sentinel.com.
New iMRI at UChicago Medicine: technology, narrative, and clinical reality. On February 3, 2026, UChicago Medicine announced the launch of a new intraoperative MRI (iMRI) suite, presenting it as a transformative advance that makes brain surgery "safer, faster and more precise." According to the institutional report, the system enables real-time imaging during surgery, reduces operative time by up to two hours, and allows surgeons to move beyond lesion removal toward treatment guided by "disease biology." Source: New iMRI tech at UChicago Medicine makes brain surgery safer, faster and more precise (UChicago Medicine, Feb 3, 2026). From the perspective of neurosurgery.education, this announcement is best understood as a promotional narrative centered on infrastructure, rather than a clinically rigorous analysis of outcomes. What iMRI genuinely offers. There is no doubt that intraoperative MRI can be a valuable technical tool in selected neurosurgical scenarios. Its main, well-established contributions include: * Detection of residual tumor before closure * Correction of brain shift affecting neuronavigation * Reduction in the need for early re-operation in specific cases These advantages are particularly relevant in infiltrative gliomas, complex epilepsy surgery, and selected functional or vascular procedures. Used appropriately, iMRI can improve the extent of resection and intraoperative decision-making. Where the narrative overreaches. The UChicago Medicine article blurs several critical distinctions. Claims about "functional MRI in real time" and treatment based on "metabolic profiles and brain networks" suggest capabilities that go well beyond what current iMRI workflows reliably deliver in routine practice. Intraoperative MRI is, in most centers, primarily an anatomical imaging tool, not a real-time functional or metabolic decision engine. Similarly, repeated use of terms such as transformative, nation-leading, and world-class is not accompanied by: * Quantitative data on extent-of-resection improvement * Evidence of reduced morbidity or improved survival * Clear patient-selection criteria Reduced operative time is presented as a universal benefit, when in reality it is highly dependent on team experience, workflow optimization, and case selection. In many settings, iMRI initially prolongs procedures during the learning phase. Technology does not replace judgment. A central concern from an educational standpoint is the implicit substitution of technology for clinical reasoning. No imaging modality compensates for: * Incorrect surgical indication * Poor anatomical strategy * Inadequate understanding of functional boundaries An iMRI suite magnifies both strengths and weaknesses of a surgical team. In expert hands it can refine decisions; in less experienced ones, it risks adding complexity without proportional benefit. The missing discussion: cost and value. Absent from the announcement is any discussion of cost-effectiveness, resource allocation, or opportunity cost. iMRI systems require: * Dedicated architectural design * MRI-compatible instrumentation * Specialized training for the entire operating room team For many hospitals - and for many neurosurgical pathologies - these investments do not translate into meaningful clinical gain. Conclusion. The arrival of an iMRI suite at UChicago Medicine reflects a significant institutional investment and a legitimate commitment to technological advancement. However, the accompanying narrative exemplifies a broader trend in academic medicine: equating technological presence with clinical excellence. From the standpoint of neurosurgery.education, excellence is not defined by the magnet in the room, but by indication, strategy, execution, and outcome. iMRI is a powerful adjunct in carefully selected cases - but it is not, by itself, a transformation of neurosurgical care. Reference: UChicago Medicine. New iMRI tech at UChicago Medicine makes brain surgery safer, faster and more precise. February 3, 2026.
UChicago Medicine to open Ralph Lauren Center at Ingalls hospital to expand access to cancer care. More in free: The Ralph Lauren Corporate Foundation has awarded a grant to the University of Chicago Medicine Comprehensive Cancer Center to establish the UChicago Medicine Ralph Lauren Center, reflecting a joint commitment to bridging gaps in cancer health and expanding cancer care in the city's vulnerable communities. The UChicago Medicine Ralph Lauren Center will offer cancer prevention, diagnosis, treatment and support services at two of the academic health system's locations, serving patients and the communities on the city's South Side and in the South Suburbs. The first site will be at UChicago Medicine Ingalls Memorial in Harvey and will launch in 2026. The other will be at the health system's main campus on the South Side within the new cancer pavilion, scheduled to open as the AbbVie Foundation Cancer Pavilion in April 2027. "We are honored that The Ralph Lauren Corporate Foundation selected UChicago Medicine to open the first Ralph Lauren Center in the Midwest and the fourth in the U.S.," said Dr. Kunle Odunsi, director of the UChicago Medicine Comprehensive Cancer Center. "The award speaks to our shared mission to improving access to cancer care in the community." The grant is part of a $25 million commitment by The Ralph Lauren Corporate Foundation to expand or establish five Ralph Lauren-named centers in communities across the United States. The funding is designed to benefit organizations that have an NCI cancer center designation, which recognizes their innovative research, leading-edge treatments, education and community-outreach programs. UChicago Medicine has been home to such a designated center since 1973. "Over the last 30 years, our mission to support communities around the world in the fight against cancer has grown into something greater than I could have ever imagined. From New York to Washington, Los Angeles and now Chicago, we are making a real impact on this disease, helping to raise awareness, improve outcomes and provide support - all thanks to the tireless work of the dedicated caregivers at our cancer centers," said Ralph Lauren, executive chairman and chief creative officer of Ralph Lauren Corporation and chair of The Ralph Lauren Corporate Foundation. Dr. Nita Lee, associate director of community outreach and engagement at UChicago Medicine Comprehensive Cancer Center, will serve as program director of the UChicago Medicine Ralph Lauren Center at both locations. To launch the program, she will work closely with UChicago Medicine's Urban Health Initiative, led by Chief Community Health Transformation Officer Catina Latham, and Ingalls Memorial oncology team, led by Director Dr. James Wallace. Cancer is a leading cause of death in Chicago's South Side and South Suburbs, where social determinants of health lead to higher cancer burdens.